Withdrawal of cerivastatin from the world market
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was...
Shranjeno v:
| izdano v: | Curr Control Trials Cardiovasc Med |
|---|---|
| Principais autores: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2001
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC59524/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11806796/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/cvm-2-5-205 |
| Oznake: |
Brez oznak, prvi označite!
|